60 Degrees Pharmaceuticals, Inc. (SXTP)
NASDAQ: SXTP · Real-Time Price · USD
1.675
-0.015 (-0.91%)
Jun 23, 2026, 2:56 PM EDT - Market open
60 Degrees Pharmaceuticals Employees
60 Degrees Pharmaceuticals had 3 employees as of December 31, 2025. The number of employees did not change compared to the previous year.
Employees
3
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$438,301
Profits / Employee
-$2,695,344
Market Cap
4.45M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 3 | 0 | - |
| Dec 31, 2024 | 3 | 0 | - |
| Dec 31, 2023 | 3 | 1 | 50.00% |
| Dec 31, 2022 | 2 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| CollPlant Biotechnologies | 39 |
| GeoVax Labs | 19 |
| FibroBiologics | 15 |
| TransCode Therapeutics | 12 |
| Revelation Biosciences | 9 |
| Dermata Therapeutics | 9 |
| Artelo Biosciences | 7 |
| Alzamend Neuro | 6 |
SXTP News
- 12 days ago - 60 Degrees executes patent licensing agreement with Florida State - TheFly
- 12 days ago - 60 Degrees Pharmaceuticals Signs Exclusive Patent License Agreement with Florida State University for Non-Prescription Use of Australian Chestnut Extract as a Botanical Supplement - GlobeNewsWire
- 15 days ago - 60 Degrees Pharmaceuticals Proxy statement: Proxy filing - Filings
- 4 weeks ago - 60 Degrees announces early enrollment of first patient in trial of tafenoquine - TheFly
- 4 weeks ago - 60 Degrees Pharmaceuticals Announces Early Enrollment of First Seasonal Patient in Clinical Trial of Tafenoquine for Patients Hospitalized with Babesiosis - GlobeNewsWire
- 4 weeks ago - H.C. Wainwright downgrades 60 Degrees on ‘untenable’ spending - TheFly
- 4 weeks ago - 60 Degrees Pharmaceuticals downgraded to Neutral from Buy at H.C. Wainwright - TheFly
- 5 weeks ago - 60 Degrees Pharmaceuticals Announces First Quarter 2026 Results - GlobeNewsWire